RT Journal Article
SR Electronic
T1 Drug advances in inflammatory bowel disease
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 378
OP 382
DO 10.7861/clinmedicine.13-4-378
VO 13
IS 4
A1 R Alexander Speight
A1 John C Mansfield
YR 2013
UL http://www.rcpjournals.org/content/13/4/378.abstract
AB The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.